Tedeschi, Alessandra
 Distribuzione geografica
Continente #
EU - Europa 338
NA - Nord America 308
AS - Asia 80
OC - Oceania 6
AF - Africa 1
Continente sconosciuto - Info sul continente non disponibili 1
Totale 734
Nazione #
US - Stati Uniti d'America 307
IT - Italia 161
SE - Svezia 102
CN - Cina 43
IE - Irlanda 35
SG - Singapore 29
DE - Germania 13
RU - Federazione Russa 7
FI - Finlandia 5
AU - Australia 4
GB - Regno Unito 4
IN - India 4
FR - Francia 3
GR - Grecia 2
IL - Israele 2
NZ - Nuova Zelanda 2
PL - Polonia 2
UA - Ucraina 2
CA - Canada 1
CH - Svizzera 1
CZ - Repubblica Ceca 1
EU - Europa 1
JP - Giappone 1
NG - Nigeria 1
TR - Turchia 1
Totale 734
Città #
Florence 80
Chandler 57
New York 45
Ashburn 40
Dublin 33
Milan 22
Singapore 20
Beijing 17
Chicago 10
Princeton 10
San Mateo 8
Wilmington 8
Rome 7
Washington 7
Dearborn 6
Moscow 6
Los Angeles 5
Norwalk 5
Acerra 4
Benalla 4
Boston 4
Pellezzano 4
Pune 4
Asti 3
Brescia 3
Helsinki 3
Redmond 3
Sesto Fiorentino 3
Bagheria 2
Berzo Inferiore 2
Bremen 2
Bruino 2
Cattolica 2
Fairfield 2
Garden City 2
Gdansk 2
Houston 2
Lappeenranta 2
Monteriggioni 2
Nanjing 2
Pottstown 2
Verona 2
Whangarei 2
Acton 1
Atlanta 1
Berlin 1
Brno 1
Casoria 1
Cuceglio 1
Dello 1
Denver 1
Forest City 1
Hebei 1
Hefei 1
Izmir 1
Jinan 1
Kunming 1
Lagos 1
London 1
Marseille 1
Nanchang 1
Naritahigashi 1
Ningbo 1
Nuremberg 1
Pavia 1
Ponte San Pietro 1
Redwood City 1
San Giovanni Teatino 1
Santa Rosa 1
Sarno 1
Seattle 1
Shenyang 1
Trieste 1
Vancouver 1
Vigliano Biellese 1
Xian 1
Zurich 1
Totale 485
Nome #
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia 66
Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia 61
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study 58
Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion 54
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 54
A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia 48
Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with ibrutinib 42
Do age, fitness and concomitant medications influence management and outcomes of CLL patients treated with ibrutinib? 41
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial 40
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study 40
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group 39
Physicians’ misperceived cardiovascular risk and therapeutic inertia as determinants of low LDL-cholesterol targets achievement in diabetes 37
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia 28
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia 23
Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia 23
Ibrutinib in patients over 80 years old with CLL: a multicenter Italian cohort 22
How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia 22
Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement 20
Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement 19
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model 19
Totale 756
Categoria #
all - tutte 4.040
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.040


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202047 3 5 1 4 2 3 6 4 16 1 2 0
2020/202117 0 3 0 1 1 2 0 0 1 6 2 1
2021/2022111 2 0 17 18 12 3 4 10 6 5 27 7
2022/2023215 34 26 16 12 15 23 4 13 28 8 32 4
2023/2024356 16 58 37 59 20 83 17 4 1 8 13 40
Totale 756